Hubei Jumpcan Pharmaceutical Co Ltd (600566.SS)
600566.SS on Shanghai Stock Exchange
52.15CNY
23 May 2018
52.15CNY
23 May 2018
Change (% chg)
¥-0.53 (-1.01%)
¥-0.53 (-1.01%)
Prev Close
¥52.68
¥52.68
Open
¥52.46
¥52.46
Day's High
¥53.52
¥53.52
Day's Low
¥51.76
¥51.76
Volume
4,398,416
4,398,416
Avg. Vol
4,610,734
4,610,734
52-wk High
¥54.30
¥54.30
52-wk Low
¥32.80
¥32.80
Revenue & Earnings Per Share
| Revenue* | Earnings Per Share** | ||
|---|---|---|---|
| FY 2018 | Mar '18 | 2,127.61 | 0.577 |
| FY 2017 | Dec '17 | 1,428.39 | 0.390 |
| Sep '17 | 1,403.45 | 0.402 | |
| Jun '17 | 1,405.36 | 0.360 | |
| Mar '17 | 1,404.81 | 0.359 | |
| FY 2016 | Dec '16 | 1,171.42 | 0.319 |
| Sep '16 | 1,152.67 | 0.292 | |
| Jun '16 | 1,197.19 | 0.292 | |
| Mar '16 | 1,156.62 | 0.268 |
*Note: Units in Millions ofRenminbi
**Note: Units in Renminbi
Consensus Estimates Analysis
| # of Estimates | Mean | High | Low | 1 Year Ago | |
|---|---|---|---|---|---|
| SALES (in millions) | |||||
| Year Ending Dec-18 | 7 | 7,155.21 | 7,386.20 | 6,919.32 | 6,901.81 |
| Year Ending Dec-19 | 7 | 8,691.12 | 9,168.26 | 8,295.43 | 8,267.36 |
| Earnings (per share) | |||||
| Year Ending Dec-18 | 7 | 1.99 | 2.09 | 1.72 | 1.85 |
| Year Ending Dec-19 | 7 | 2.49 | 2.61 | 2.14 | 2.25 |
Sales and Profit Figures in China Yuan Renminbi (CNY);
Valuation Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| P/E Ratio (TTM) | 27.73 | 30.95 | 32.75 | |
| P/E High - Last 5 Yrs. | 31.48 | 40.70 | 45.73 | |
| P/E Low - Last 5 Yrs. | 17.01 | 23.63 | 24.23 | |
| Beta | 0.47 | 0.89 | 0.88 | |
| Price to Sales (TTM) | 5.81 | 3.94 | 5.71 | |
| Price to Book (MRQ) | 8.29 | 4.81 | 5.37 | |
| Price to Tangible Book (MRQ) | 9.32 | 5.61 | 6.94 | |
| Price to Cash Flow (TTM) | -- | 22.91 | 23.33 | |
| % Owned Institutions | -- | 1.21 | 2.16 | |
Dividends
| Company | industry | sector | ||
|---|---|---|---|---|
| Dividend Yield | 1.98 | 1.56 | 1.50 | |
| Dividend Yield - 5 Year Avg | 1.74 | 1.57 | 1.51 | |
| Dividend 5 Year Growth Rate | 135.87 | 4.47 | 5.32 | |
| Payout Ratio(TTM) | 54.95 | 45.35 | 43.29 | |
Growth Rates
| Company | industry | sector | ||
|---|---|---|---|---|
| Sales (MRQ) vs Qtr. 1 Yr. Ago | 17.39 | 3.69 | 9.21 | |
| Sales (TTM) vs TTM 1 Yr. Ago | 20.84 | 4.83 | 5.69 | |
| Sales - 5 Yr. Growth Rate | 81.05 | 10.08 | 10.32 | |
| EPS (MRQ) vs Qtr. 1 Yr. Ago | 23.04 | 16.38 | 19.38 | |
| EPS (TTM) vs TTM 1 Yr. Ago | 31.02 | -- | -- | |
| EPS - 5 Yr. Growth Rate | 82.83 | 9.88 | 10.77 | |
| Capital Spending - 5 Yr. Growth Rate | 39.73 | 15.52 | 15.47 | |
Financial Strength
| Company | industry | sector | |
|---|---|---|---|
| Quick Ratio (MRQ) | 1.69 | 2.12 | 2.19 |
| Current Ratio (MRQ) | 1.84 | 2.90 | 2.98 |
| LT Debt to Equity (MRQ) | 0.00 | 9.88 | 12.17 |
| Total Debt to Equity (MRQ) | 3.15 | 13.86 | 16.44 |
| Interest Coverage (TTM) | -- | 35.89 | 32.81 |
Profitability Ratios
| Company | industry | sector | ||
|---|---|---|---|---|
| Gross Margin (TTM) | 83.25 | 54.81 | 54.45 | |
| Gross Margin - 5 Yr. Avg. | 84.42 | 52.15 | 52.21 | |
| EBITD Margin (TTM) | 23.40 | -- | -- | |
| EBITD - 5 Yr. Avg | 21.66 | 18.57 | 10.96 | |
| Operating Margin (TTM) | 23.47 | 14.36 | 4.73 | |
| Operating Margin - 5 Yr. Avg. | 19.31 | 14.52 | 6.40 | |
| Pre-Tax Margin (TTM) | 24.39 | 14.82 | 5.57 | |
| Pre-Tax Margin - 5 Yr. Avg. | 20.53 | 14.91 | 6.82 | |
| Net Profit Margin (TTM) | 20.97 | 11.08 | 1.87 | |
| Net Profit Margin - 5 Yr. Avg. | 17.58 | 11.20 | 3.09 | |
| Effective Tax Rate (TTM) | 14.03 | 23.16 | 23.04 | |
| Effective Tax Rate - 5 Yr. Avg. | 14.39 | 23.42 | 23.95 | |
Efficiency
| Company | industry | sector | ||
|---|---|---|---|---|
| Revenue/Employee (TTM) | 1,003,176 | 938,098,556 | 847,034,055 | |
| Net Income/Employee (TTM) | 210,358 | 110,370,574 | 99,640,144 | |
| Receivable Turnover (TTM) | 3.47 | 5.63 | 5.78 | |
| Inventory Turnover (TTM) | 4.77 | 2.59 | 3.35 | |
| Asset Turnover (TTM) | 1.08 | 0.95 | 0.92 | |
Management Effectiveness
| Company | industry | sector | ||
|---|---|---|---|---|
| Return on Assets (TTM) | 22.73 | 11.40 | 10.95 | |
| Return on Assets - 5 Yr. Avg. | 20.57 | 12.91 | 12.32 | |
| Return on Investment (TTM) | 31.21 | 14.84 | 14.38 | |
| Return on Investment - 5 Yr. Avg. | 30.33 | 16.88 | 16.11 | |
| Return on Equity (TTM) | 31.81 | 16.34 | 16.07 | |
| Return on Equity - 5 Yr. Avg. | 31.05 | 17.98 | 17.39 | |
| 1 Year | 3 Year | 5 Year | |
|---|---|---|---|
| Sales % | 24.15 | 24.10 | 81.05 |
| EPS (TTM) % | 33.17 | 21.07 | 82.83 |
| Dividend % | 4.29 | -- | 135.87 |
Note: Units in Millions of US Dollars
Performance for Hubei Jumpcan Pharmaceutical Co Ltd
Note:: Rank is a percentile that ranges from 0 to 99, with 99 = best.
- BRIEF-Hubei Jumpcan Pharmaceutical to pay cash dividend of 10 yuan per 10 shares (before tax) for 2017
- BRIEF-Hubei Jumpcan Pharmaceutical's Q1 Net Profit Up 60.6 Percent Y/Y
- BRIEF-Hubei Jumpcan Pharmaceutical's 2017 Net Profit Up 31.0 Pct Y/Y At 1.2 Bln Yuan
- BRIEF-Hubei Jumpcan Pharmaceutical unit obtains high-tech enterprise recognition and to enjoy tax preference
- BRIEF-Hubei Jumpcan Pharmaceutical unit receives GMP certificate
Institutional Holders
| % Shares Owned: | 8.08% |
| # of Holders: | 57 |
| Total Shares Held: | 65,417,666 |
| 3 Mo. Net Change: | 6,221 |
| # New Positions: | 0 |
| # Closed Positions: | 1 |
| # Increased Positions: | 2 |
| # Reduced Positions: | 2 |
| # Net Buyers: | 0 |
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.